Paediatric renal transplantation: moving forward in the field by Mamode, N & Marks, SD
Paediatric renal transplantation: 
moving forward in the field 
 
Nizam Mamode1, Stephen D Marks2 
Editorial commentary for “Topical Collection” 
 
1Department of Transplantation 
Guy's and St Thomas' NHS Foundation Trust 
London  
SE1 9RT 
England, United Kingdom. 
2Department of Paediatric Nephrology 
Great Ormond Street Hospital for Children NHS Foundation Trust 
Great Ormond Street 
London 
WC1N 3JH 
England, United Kingdom. 
 
*Address correspondence to: 
Professor Nizam Mamode 
Renal Offices, 6th Floor Borough Wing 
Guy’s Hospital 
Great Maze Pond 
London, SE1 9RT 
England, United Kingdom. 
 
Telephone:  +44 20 7188 8476 
Fax:  +44 20 7188 5646 
e-mail:  nizam.mamode@gstt.nhs.uk 
Keywords:  
 

















The field of renal transplantation is becoming more complicated with both clinicians and 
academics needing to know the latest advances. Although we learn from adult practice, 
children are not small adults and there are inherent differences in anatomy, physiology, 
pathophysiology and immunology from infants to children to adolescents with their 
developing immune system. This makes the management of patients more complex for both 
physicians and surgeons. Children may be the recipients of multiple renal transplants, so 
subsequent sensitisation is a key issue. We aim for close HLA matching, but there is 
uncertainty about when poorer matching is outweighed by the detrimental effects of longer 
waiting on the deceased donor list. Should we enter antibody incompatible donor-recipient 
pairs into National Kidney Sharing Schemes, and should we include compatible pairs in order 
to achieve better matching ? Some children will be lucky enough to receive an altruistic 
living donor but many children will remain on the deceased donor renal transplant waiting 
list. Should we consider donation after cardiac death (DCD; non-heart beating) donors and 
marginal donors for some prospective paediatric renal transplant recipients (pRTR) ? What is 
the role of ex-vivo normothermic perfusion for such cases ? Should we accept neonatal and 
infant en bloc donors for prospective pRTR, with the increased thrombotic risk which that 
may entail ? Which children should receive induction agents for their first renal transplant 
when they may receive multiple renal transplants during their childhood? Should we use 
monoclonal and polyclonal antibodies more readily in adolescents who are at risk of losing 
their renal allografts due to non-adherence ? Would belatacept, given by monthly infusion, 
help with adherence to conventional immunosuppression for these patients ? 
 
Historically, we take the evidence from our adult renal transplant colleagues but we are now 
performing more studies and clinical trials, including multi-centre randomised controlled 
studies in pRTR. This is increasing our knowledge but also the armamentarium of available 
immunosuppressive agents, in a group of patients who are at increased risk of infectious 
complications. There is increased Epstein-Barr virus naivety resulting in increased rates of 
post-transplant lymphoproliferative disorder in our paediatric population. However, some 
children require increased immunosuppression, such as those undergoing blood group ABO 
incompatible and/or HLA incompatible renal transplants as well as those patients developing 
antibody-mediated rejection. Is there a role for mTOR inhibitors to promote long term graft 
survival, and can newer depleting agents such as bortezomib be used? 
 
This Topical Collection in Pediatric Nephrology aims to make it easier for the multi-
disciplinary team to get answers to these questions by drawing together the latest up-to-date 
basic science and research papers as well as clinically relevant reviews on paediatric renal 
transplantation into one place.  
For example we have upcoming invited reviews on the new generation of ABO antibody 
diagnostics, on tissue damage processes and mitochondrial mechanisms in ischemia 
reperfusion injury, as well as how proteomics could give insight into tissue damage and 
repair processes. We will feature reviews on preventing delayed graft function, managing 
failing allografts and transitioning of adolescent renal transplant recipients. We will also 
focus on the future of transplantation, looking at state of the art immunosuppression 
protocols, developments in regulatory cell and stem cell therapies and cutting-edge research 
in growing organs for transplantation. 
We bring this exciting venture to you with the thoughts of improving the outcomes of our 
patients and their dedicated families who tirelessly support them. 
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